{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Ftoga-podcast.simplecast.com%2Fepisodes%2Fbraf-mutated-nsclc-in-australia-dQa8n9vz","width":444,"version":"1.0","type":"rich","title":"The Evolving Landscape of BRAF-Mutated NSCLC in Australia","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/37b381d6-a6e7-4025-a6ac-23a0ce7134b8/d812b408-cc4a-44aa-99b2-801e49ea2f82/podcast_creative_braf.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f52bb1d2-22f8-4160-98a5-b4df5ffd34a6\" height=\"200\" width=\"100%\" title=\"The Evolving Landscape of BRAF-Mutated NSCLC in Australia\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide, leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer. Joined by Prof Ahn Myung-ju, a Medical Oncologist at Hanyang University Medical Centre in South Korea as well as Co-chair for the upcoming World Lung Cancer Conference, and A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital in Sydney. The panel discusses the clinical characteristics and incidence of this molecular subset, the critical need for upfront comprehensive genomic testing, key clinical trial data for targeted therapies, and practical strategies for managing treatment-specific side effects like pyrexia syndrome."}